Investigating a new target for treating pancreatic cancer
Targeting the MICAL2 signaling axis in pancreatic cancer
This study is looking at a specific enzyme called MICAL2 that is found in higher amounts in pancreatic cancer, and the researchers want to see how it affects the growth of cancer cells to help find better treatments for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10676946 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer that is difficult to treat with current therapies. The team is exploring the role of a specific enzyme, MICAL2, which is found to be overexpressed in PDAC and linked to poor patient outcomes. By analyzing tumor samples and cell lines, the researchers aim to understand how MICAL2 affects cell growth and division, potentially leading to new treatment strategies. The approach involves examining the epigenetic changes in tumors to identify how MICAL2 can be targeted for therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who have not responded well to existing treatments.
Not a fit: Patients with other types of pancreatic cancer or those who are in advanced stages of the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be viable.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Lowy, Andrew M — University of California, San Diego
- Study coordinator: Lowy, Andrew M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.